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Loci Shared by At Least Two Cancer Types
A full list of authors and affiliations appears at the end of the article.
Abstract
Breast, ovarian, and prostate cancers are hormone-related and may have a shared genetic basis but 
this has not been investigated systematically by genome-wide association (GWA) studies. Meta-
analyses combining the largest GWA meta-analysis data sets for these cancers totaling 112,349 
cases and 116,421 controls of European ancestry, all together and in pairs, identified at P < 10−8 
seven new cross-cancer loci: three associated with susceptibility to all three cancers 
(rs17041869/2q13/BCL2L11; rs7937840/11q12/INCENP; rs1469713/19p13/GATAD2A), two 
breast and ovarian cancer risk loci (rs200182588/9q31/SMC2; rs8037137/15q26/RCCD1), and 
two breast and prostate cancer risk loci (rs5013329/1p34/NSUN4; rs9375701/6q23/L3MBTL3). 
Index variants in five additional regions previously associated with only one cancer also showed 
clear association with a second cancer type. Cell-type specific expression quantitative trait locus 
and enhancer-gene interaction annotations suggested target genes with potential cross-cancer roles 
at the new loci. Pathway analysis revealed significant enrichment of death receptor signaling genes 
near loci with P < 10−5 in the three-cancer meta-analysis.
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Introduction
Breast, ovarian and prostate cancer are hormone-related cancers (1). Breast and ovarian 
cancer share several environmental and lifestyle risk factors that affect exogenous or 
endogenous estrogen exposure, while the androgens play a key role in the pathophysiology 
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of prostate cancer. Collectively, cancers at these three sites accounted for more than 420,000 
new cases, or over 25% of all cancers diagnosed, in the United States in 2012 (2).
All three cancers are known to aggregate in the same families (3–5). The effects of a shared 
environment and of rare, highly penetrant alleles in established cancer predisposition genes 
explain only a part of the observed familial clustering (6). This suggests that there exist 
common, low-penetrance susceptibility variants with shared effects across these cancer 
types. Since 2007, genome-wide association studies (GWAS), replication studies, and a 
custom genotyping effort focused individually on breast, ovarian, and prostate cancers have 
identified multiple risk loci specific to each cancer (summarized in refs. (7–9)). The same 
studies have also identified three susceptibility loci where the most strongly associated 
single nucleotide polymorphism (SNP) or the index SNP exhibits pleiotropy and is common 
to two of the cancer types (10–15). Moreover, in several other regions, separate index SNPs 
for risk of at least two of the cancers are found in close proximity and the underlying signal 
may well be pleiotropic (16). However, genetic association studies for breast, ovarian, and 
prostate cancers to date have been designed to be cancer site-specific. Pleiotropy between 
them has not itself been leveraged as the basis for systematic genome-wide discovery of 
completely new cancer risk loci – loci that share an association with at least two, if not all 
three, of the cancers.
Given this background, we combined data from the largest and most recently published 
genome-wide association meta-analysis for susceptibility to breast cancer (7), ovarian cancer 
(8), and prostate cancer (9), in a single three-cancer meta-analysis of 228,770 individuals, 
and in pairwise combinations. We hypothesized that the substantial gain in power afforded 
by the cross-cancer meta-analyses would enable the identification, at genome-wide 
significance, of risk loci sharing an association with more than one of the three cancers that 
are novel for each of the cancers (17). Pleiotropic alleles at these loci may be modestly 
associated with each of the cancers and not previously detected at the standard threshold for 
genome-wide significance (P < 5 × 10−8) in single-cancer studies due to sample size 
constraints. We also investigated whether the index SNP in regions so far known to contain 
associations with only one cancer out of breast, ovarian, or prostate cancer showed clear 
evidence for association with another cancer out of the three. Further, at the rare variant end 
of the genetic association spectrum, the identification of rare alleles that confer inherited 
susceptibility to multiple cancers in genes such as BRCA1, BRCA2, and TP53 has yielded 
critical insights into their role in cancer etiology (18,19). Motivated by this observation, we 
annotated the new cross-cancer risk loci using cell-type specific expression quantitative trait 
locus (eQTL) and enhancer-gene interaction maps, and performed enrichment analysis for 
molecular pathways in the top regions spanning breast, ovarian, and prostate cancer to 
identify putative shared target genes and mechanisms potentially driving common genetic 
susceptibility across these hormone-related cancers.
Results
Study Populations
We used summary statistics for association with cancer risk from the largest and most 
recently published meta-analysis of GWA, replication and custom genotyping case-control 
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studies for each cancer (7–9). These meta-analyses included 62,533 women with breast 
cancer (including 12,412 women with estrogen receptor (ER)-negative tumors) and 60,976 
controls, 15,437 women with invasive epithelial ovarian cancer (including 9,627 women 
with serous tumors) and 30,845 controls, and 34,379 men with prostate cancer and 33,164 
controls. All individuals were of European ancestry and a total of 8,564 controls overlapped 
between the breast and ovarian cancer studies. The summary statistics were available for 
variants with minor allele frequency (MAF) > 0.5% that had either been genotyped or 
imputed independently in the breast, ovarian and prostate cancer studies using the 1000 
Genomes Project (March 2012 release) European reference panel.
New Associations with a Second Cancer at Known Single-cancer Risk Loci
We listed the published index SNP at each of the 92, 18 and 100 loci known to be associated 
with breast, ovarian and prostate cancer susceptibility, respectively, in European-ancestry 
populations (Supplementary Table S1). The list comprised 207 unique SNPs after 
accounting for the three SNPs that were each an index SNP for two cancers (rs10069690 at 
5p15 and rs8170 at 19p13 for breast and ovarian cancer, and rs4245739 at 1q32 for breast 
and prostate cancer; refs. (10–15)). Separate index SNPs for two of the cancers were within 
1 Mb of each other in 21 genomic regions, including two regions (at 6p22 and 8q24) that 
contained index SNPs for all three cancers (Supplementary Table S2).
Scanning for these 207 SNPs using the summary data identified novel associations with 
breast cancer susceptibility at the ovarian cancer index SNP rs635634 at 9q34/ABO (PBrCa = 
8.1 × 10−7) and at the prostate cancer index SNPs rs6763931 at 3q23/ZBTB38 (PBrCa = 1.2 
× 10−6) and rs11214775 at 11q23/HTR3B (PBrCa = 5.2 × 10−5) with consistent direction of 
allelic effect between the previously reported and novel associations across cancer types 
(Table 1). Further, the risk (T) allele of the breast cancer index variant in BRCA2, 
rs11571833 (MAF = 0.8%), was associated with ovarian cancer risk (POvCa = 6.4 × 10−8 for 
serous invasive ovarian cancer; odds ratios and additional details in Table 1) while the 
protective (T) allele of the breast cancer index SNP rs1830298 at 2q33/ALS2CR12 was 
associated with prostate cancer risk (PPrCa = 1.3 × 10−6; Table 1). Thus, index SNPs at five 
loci so far known to be associated with only one cancer type demonstrated strong evidence 
for association with a second cancer type, out of breast, ovarian, and prostate cancer, at a 
significance level of 6 × 10−5 after Bonferroni correction for testing 207 SNPs in four ways 
(breast and ovarian cancer, breast and prostate cancer, ovarian and prostate cancer, and ER-
negative breast and serous ovarian cancer). There was no known index SNP associated with 
the second cancer type within 1 Mb on either side of any of the new signals.
Meta-analysis of Breast, Ovarian and Prostate Cancer Genome-wide Association Meta-
analysis Data
Having examined the index SNPs at established risk loci for each cancer to uncover new 
cross-cancer association signals, we conducted a fixed-effects meta-analysis using the 
breast, ovarian and prostate cancer summary statistics for all variants that were nominally 
associated (P < 0.05) with each of the three cancers. In effect, our study design enabled 
independent replication of findings reaching P < 0.05 for association with susceptibility to 
one cancer type in data from the two other cancer types. We reasoned that this approach 
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could identify previously unrecognized cancer risk loci that were shared by breast, ovarian 
and prostate cancer and achieved genome-wide significance only after combining data from 
the three cancers.
The meta-analysis identified 267 alleles spanning 18 independent loci that were associated at 
P < 10−8 with breast, ovarian and prostate cancer susceptibility with the same direction of 
effect across all three cancers (Manhattan plot in Figure 1; Supplementary Table S3). The 
threshold for genome-wide significance was set at a more stringent P < 10−8 compared to the 
standard P < 5 × 10−8 to correct for multiple comparisons arising from the fact that we 
searched for associations shared between cancer types in five possible ways (breast, ovarian 
and prostate cancer, breast and ovarian cancer, breast and prostate cancer, ovarian and 
prostate cancer, and ER-negative breast and serous ovarian cancer; the pairwise searches are 
described in the next section). Moreover, it is possible to obtain a genome-wide significant 
signal in a meta-analysis of three cancers in the setting of a particularly strong association 
between a variant and a subset of one or two of the cancers and no association with the 
remaining cancer(s). We addressed this possibility by applying the association analysis 
based on subsets (ASSET; ref. (20)) method to test whether the best association model for 
each newly identified index variant involved all three cancers, as would be expected for true 
cross-cancer signals. Model selection using ASSET demonstrated that all three cancers 
contributed to the signal at the most significantly associated variant at 13 of the 18 loci 
(Supplementary Table S3, ASSET column). None of these 13 index variants showed 
significant heterogeneity in the per-allele odds ratio between the three cancers further 
confirming consistent pan-cancer effects (Cochran’s Q-test for heterogeneity, Phet > 0.05).
To account for correlation between the breast and ovarian cancer studies due to the 8,564 
controls shared between them, we repeated the meta-analysis for the 13 index variants using 
a statistical adjustment for studies with overlapping controls that required only summary 
statistics and exact sample counts contributing to the association at each variant from the 
corresponding data sets (21). Two of the variants fell just short while 11 remained at P < 
10−8 after this adjustment (Supplementary Table S3, Padjusted column). Eight of these 11 loci 
were less than 1 Mb from a known index SNP for at least one of the three cancers. Details of 
the eight susceptibility loci including linkage disequilibrium (LD) information with respect 
to known index SNPs are also presented in Supplementary Table S3.
The three remaining loci were over 1 Mb away from known index SNPs for any of the three 
cancers and indexed by the variants rs17041869 (in BCL2L11 at 2q13; Pmeta = 5.1 × 10−9; 
Table 2A), rs7937840 (in INCENP at 11q12; Pmeta = 5.0 × 10−9), and rs1469713 (in 
GATAD2A at 19p13; Pmeta = 3.4 × 10−10). They represent entirely new association signals 
for all three cancers discovered at genome-wide significance (P < 10−8) by leveraging the 
shared genetic architecture of breast, ovarian and prostate cancer (P-values for each cancer 
type in Table 2A; regional association plots in Supplementary Fig. S1A–C). While the newly 
identified index variant rs1469713 itself was 960 kb from a known breast cancer index SNP 
rs4808801, 42 of the 89 variants in the new 19p13/GATAD2A region that were correlated 
with rs1469713 and reached P < 10−8 in the three-cancer meta-analysis were between 1 to 
1.2 Mb away from rs4808801 (Supplementary Fig. S1C). Furthermore, rs1469713 and 
rs4808801 were not linked (r2 = 0.001 in the European populations from the 1000 Genomes 
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Project) and the association at rs1469713 remained on analysis of the breast cancer data 
conditioning on rs4808801, confirming independence of the new signal from the known one 
(Supplementary Table S4, which includes three-cancer meta-analysis results for rs1469713 
undertaken using results from the conditional analysis). We also confirmed that the three 
new index SNPs were not correlated with known breast, ovarian or prostate cancer index 
SNPs up to 10 Mb away on either side (r2 < 0.01 in 1000 Genomes European populations). 
Figure 2A shows forest plots of odds ratios and 95% confidence intervals corresponding to 
association of the three novel index variants with each cancer separately and on meta-
analysis. While rs17041869 had been genotyped, the two other index variants had been 
imputed with accuracy, r2 ≥ 0.89 (Table 2A).
Pairwise Meta-analyses using the Breast, Ovarian and Prostate Cancer Data
To identify new risk loci in common specifically to two of the three cancers, we combined 
data from the three cancer types in pairs using fixed-effects meta-analyses. We also 
conducted an additional meta-analysis for shared susceptibility to ER-negative breast and 
serous ovarian cancer as the two previously reported index SNPs known to be shared 
between breast cancer and ovarian cancer are specific to these two subtypes (rs10069690 
and rs8170 (10–13)). Before examining results from each pairwise meta-analysis, we 
excluded all variants within 1 Mb of known index SNPs for either or both cancer types 
contributing to the meta-analysis to avoid detecting signals unduly driven by established 
associations in one or both cancer types contributing to the meta-analysis. We identified new 
shared associations with breast and ovarian cancer risk at rs200182588 (in SMC2 at 9q31; 
Pmeta = 8.9 × 10−9 after adjusting for overlapping controls) and rs8037137 (near RCCD1 at 
15q26; Pmeta = 9.1 × 10−10 after adjustment), and with breast and prostate cancer risk at 
rs5013329 (in NSUN4 at 1p34; Pmeta = 1.8 × 10−11) and rs9375701 (in L3MBTL3 at 6q23; 
Pmeta = 3.4 × 10−10). Full results for the four new index SNPs are presented in Table 2B, 
forest plots in Figure 2B, and regional association plots in Supplementary Fig. 1D–G. These 
SNPs were not correlated with known index SNPs for the corresponding individual cancer 
types up to 10 Mb away on either side (r2 < 0.01 in 1000 Genomes European populations). 
ASSET confirmed contributions from both cancer types to each new signal, none of them 
displayed significant heterogeneity in the per-allele odds ratio (Phet > 0.05), and the index 
variants had been imputed with accuracy, r2 ≥ 0.81 (Table 2B). No new locus was identified 
at genome-wide significance (P < 10−8) in the ovarian and prostate cancer and in the 
subtype-specific ER-negative breast and serous ovarian cancer meta-analyses after excluding 
all variants within 1 Mb of known index SNPs for either or both cancer types contributing to 
the corresponding meta-analyses.
Further, there is some evidence that alleles that increase risk of one cancer confer protection 
from another cancer (notably at rs4245739 which is a known index SNP for both breast and 
prostate cancer). Therefore, we used the two-sided subset function implemented in ASSET 
to also look for alleles in the three-cancer meta-analysis that were associated with all three 
cancers (with a combined ASSET P < 10−8) but where the direction of allelic effect on one 
of the cancers was opposite to that observed for the other cancer types (details in Methods). 
To search for such alleles in each pairwise meta-analysis, we reversed the signs on the effect 
size estimates in one of the two data sets and repeated fixed-effects meta-analysis (22). 
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However, no novel loci were identified at P < 10−8 in the search for shared alleles with 
opposite effects on risk of different cancer types out of the three cancers using either 
approach.
Of the seven new loci identified by the three-cancer and pairwise meta-analyses, the index 
SNP at 2q13 is a genotyped SNP while the index SNPs at the remaining loci were well 
imputed with accuracy, r2 ≥ 0.81 and had MAF ≥ 12%. Imputation was conducted 
independently for data from each cancer type and imputation accuracy estimates were 
consistent across cancer types. In each of the three single-cancer genome-wide association 
meta-analyses that contributed to this three-cancer study, we have demonstrated high 
concordance between imputed and genotyped SNP results for common SNPs (MAF > 5%) 
identified at standard genome-wide significance (P < 5 × 10−8) that have imputation 
accuracy > 0.80. Finally, for four of the six new loci where the index SNP was an imputed 
SNP, we were also able to identify a genotyped SNP in the same region that was also 
genome-wide significant (P < 10−8; Supplementary Table S5 provides results for the most 
significantly associated genotyped SNP at each of these six loci).
Expression QTL Analyses Suggest Target Genes Shared Across Relevant Cell Types at 
New Loci
We carried out cis-expression quantitative trait locus (eQTL) analyses for the seven new 
index variants (listed in Table 2) and all genes up to 1 Mb on either side of each variant 
using breast (n = 183), ovarian (n = 85), and prostate (n = 87) normal tissue samples from 
the Genotype-Tissue Expression (GTEx) Project (23). The risk (T) allele of the breast and 
prostate cancer index variant rs9375701 was significantly associated with reduced 
expression of L3MBTL3 in both breast (P = 3.5 × 10−9) and prostate (P = 8.9 × 10−7) tissue 
(box plots in Supplementary Fig. S2A). There were no significant associations (P < 0.05) 
between this SNP and the expression level of any other gene in the same region in either cell 
type. A consistent cross-cell type association was also observed between the risk (T) allele 
of the breast and ovarian cancer index variant rs8037137 and decreased expression of 
RCCD1 in both breast (P = 1.1 × 10−15) and ovarian (P = 1.1 × 10−5) tissue (box plots in 
Supplementary Fig. S2B). Some of the index variants also yielded eQTL associations that 
were nominally significant in only one of the three cell types (full results in Supplementary 
Table S6). Further, we looked up two of the seven index variants that were reported in a 
large database of eQTLs from peripheral blood samples (n = 5,311; ref. (24)) and found an 
association between the risk (G) allele of the three-cancer index SNP rs1469713 and 
increased expression of GATAD2A (P = 9.8 × 10−198) and replicated the association 
between the T allele of rs9375701 and decreased expression of L3MBTL3 (P = 4.7 × 
10−125).
Cell-type Specific Enhancer Maps Suggest Target Genes Shared Across Relevant Cell 
Types at New Loci
Expression QTL analysis may not always be able to detect functionally important variant-
gene relationships over background noise given small sample sizes of eQTL data sets, the 
dynamic nature of gene expression, and the likely modest biological effects of risk variants 
(25). Disease-associated genetic variation has been found enriched in cell-type specific 
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enhancer elements. Therefore, as an alternative strategy to identify potential cross-cancer 
susceptibility genes, we annotated all variants with P < 10−8 at the seven new loci (variant 
counts in Table 2) using maps of enhancers in breast, ovarian and prostate cell types (26–
28). We intersected these maps with computationally predicted enhancer-gene interactions in 
the same cell types (26–28) as well as experimentally derived interactions that were only 
available for breast cells (HMEC and MCF7 profiled using Hi-C and ChIA-PET, 
respectively; refs. (29,30)).
Two intronic SNPs in GATAD2A out of the 89 variants with P < 10−8 at the 19p13 three-
cancer risk locus (rs2916068 and rs2965183; Figure 3; Supplementary Table S7) were 
located in enhancers in normal and cancerous breast (HMEC and MCF7, respectively), 
normal ovarian (ovary, UCSD) and prostate cancer (LNCaP) cells and in each instance, this 
enhancer was predicted to interact with GATAD2A. A direct physical interaction between 
rs2916068 and the GATAD2A promoter was additionally confirmed in the MCF7 breast 
cancer cells assayed by ChIA-PET. The index SNP rs17041869 at the 2q13 three-cancer risk 
locus mapped to an enhancer in breast (MCF7) and prostate (LNCaP) cancer cells and in 
both cases, this enhancer was predicted to interact with BCL2L11 (Figure 4; Supplementary 
Table S7). Notably, while evidence for BCL2L11 as a target gene was not found in ovarian 
cells by enhancer-gene interaction annotation, the eQTL analysis did show a marginally 
significant association between the risk-conferring (G) allele of rs17041869 and elevated 
expression of BCL2L11 in normal ovarian tissue samples (Povary_eQTL= 0.048), this being 
the only significant cis-association detected for rs17041869 in any of the three cell types 
(Supplementary Table S6).
At the 1p34 breast and prostate cancer region, several of the 218 P < 10−8 variants 
overlapped enhancers that interacted with NSUN4 in breast (MCF7; interaction confirmed 
by ChIA-PET) and prostate (LNCaP) cancer cells (Supplementary Table S7). SNP 
rs17361950 intersected enhancers interacting with FAAH in MCF7 (confirmed by ChIA-
PET) and LNCaP while the indels chr1:46505589:I and chr1:46505785:I intersected 
enhancers targeting PIK3R3 in LNCaP and in the breast cancer cell line HCC1954 
(Supplementary Table S7). The risk (T) allele of the index SNP rs5013329 at the same locus 
was significantly associated with lower expression of NSUN4 in breast (Pbreast_eQTL = 
0.001) and the long non-coding RNA (lncRNA) gene RPS15AP10 in prostate (Pprostate_eQTL 
= 0.02) normal tissues (Supplementary Table S6). These findings collectively implicate 
NSUN4 as the strongest shared functional candidate at 1p34. In addition to eQTL and 
enhancer mapping, we also annotated P < 10−8 variants in the seven regions using the 
HaploReg (31), lncRNASNP (32), and PolymiRTS (microRNA and miRNA target region 
annotation; ref. (33)) databases (Supplementary Table S8).
Pathway Analysis Implicates Apoptosis as a Potential Mechanism for Susceptibility to All 
Three Cancers
Finally, we used pathway analysis to explore the genome-wide significant regions and the 
fraction of associations just failing to reach this threshold in the meta-analysis of data from 
the three cancers. We took all alleles (regardless of proximity to known index SNPs for any 
of the three cancers) that met three criteria: (i) P < 10−5 in the three-cancer meta-analysis, 
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(ii) same direction of effect across all three cancers, and (iii) no significant heterogeneity in 
the per-allele odds ratio between cancers (Phet > 0.05). These 884 alleles were then subjected 
to LD-based ‘pruning’ to leave 69 independent alleles (details in Methods). Taking regions 
up to 1 Mb on either side of the 69 alleles and merging overlapping regions yielded 51 
intervals harboring a shared association with breast, ovarian and prostate cancer at P < 10−5. 
We used the Interval Enrichment tool (INRICH; ref. (34)) to permute 5,000 matched 
intervals and tested for enrichment of pathways from four databases (KEGG, Biocarta, 
Reactome, and Gene Ontology), correcting for multiple comparisons separately in each 
database. Only one pathway, from Biocarta, survived this correction: 8/32 genes from the 
induction of apoptosis through DR3 and DR4/5 Death Receptors signaling pathway 
(CASP9, LMNA, CASP7, TNFSF10, TNFRSF10A, TNFRSF10B, RELA, and FADD; ref. 
(35)) were located in 7/51 intervals (INRICH analysis Pempirical = 0.0004, Pcorrected = 0.01; 
top SNP in each interval listed in Supplementary Table S9). BCL2L11 – the likely target of 
the new 2q13 three-cancer risk locus – is not a member of this pathway but given that this 
gene is a known apoptosis facilitator (36,37), we also checked for and found interactions 
between BCL2L11 and several members of the Biocarta Death Receptor signaling pathway 
(Supplementary Fig. S3; details in Methods). Moreover, other apoptosis-related pathways 
that did contain BCL2L11 were among the top pathways in the Reactome and Gene 
Ontology databases (Pempirical = 0.04—0.006; Supplementary Table S10).
Discussion
Here we report findings from the first cross-cancer type genome-wide association meta-
analysis focused on three hormone-related cancers. Performing a series of fixed-effects 
meta-analyses to cover all possible combinations of these three cancers, and a subtype-
specific analysis for ER-negative breast and serous ovarian cancers, we identified three loci 
demonstrating shared association with breast, ovarian, and prostate cancer risk, two with 
breast and ovarian cancer risk, and two with breast and prostate cancer risk. Each of these 
seven loci was over 1 Mb away from previously identified risk loci and had the same 
direction of allelic effect for the corresponding individual cancer types. They were followed 
up using cell-type specific eQTL and enhancer data to identify the gene(s) likely to be 
targeted by the risk variants that are in common across cell types. Although we prioritized 
discovery of cross-cancer risk loci that were novel for each of the cancers, we also found 
that the index SNP in five additional regions previously known to be associated with only 
one of the three cancers showed robust evidence for pleiotropic association with a second 
cancer type out of the three. Only one of these five showed opposite effects on the risk of 
two cancer types (rs1830298, a known breast cancer index SNP at 2q33, found to be 
associated with prostate cancer) possibly reflecting tissue-specific regulatory mechanisms 
and/or tissue-specific modulation by environmental factors at this locus.
Annotation of the new 19p13 three-cancer susceptibility locus revealed that two strongly 
associated variants (P < 10−8) intersected overlapping enhancer elements interacting with 
GATAD2A in breast, ovarian, and prostate cell types. GATAD2A is a subunit of the 
nucleosome remodeling and histone deacetylase (NuRD) complex, a chromatin-level 
regulator of transcription with a number of important and emerging roles in cancer biology 
(38). At the level of transcription, the NuRD complex is recruited by tissue-specific 
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oncogenic transcription factors to repress the expression of tumor suppressor genes while at 
the post-translational level, this complex has been shown to deacetylate p53 to inactivate 
p53-induced apoptosis. The index variant at the 2q13 three-cancer risk locus was located in 
enhancers targeting the apoptosis facilitator BCL2L11 in breast and prostate cancers cells 
and was associated with expression of the same gene in normal ovarian cells (36,37). 
Interestingly, this variant rs17041869 is 53 kb away from rs6738028, a genome-wide 
significant index SNP for serum dehydroepiandrosterone sulphate (DHEAS) concentrations 
(39). Correlation between the two variants was r2 = 0.08 and D′ = 1, with the cancer risk-
conferring G allele (frequency = 0.10) of rs17041869 always segregating with the C allele 
(frequency = 0.59) of rs6738028 in 1000 Genomes European populations (although we did 
not find rs6738028 itself to be associated with cancer risk). Secreted largely by the adrenal 
glands, DHEAS is the most abundant circulating steroid in the human body and is converted 
into active androgens and estrogen in the relevant peripheral tissue (40,41). DHEAS levels 
have previously been linked to increased risk of breast cancer but the direction of its 
associations with cancers of the prostate and ovary are less clear (42–44). The DHEAS 
GWAS also showed that the C allele of rs6738028 was associated with higher DHEAS levels 
and significantly lower expression of BCL2L11 in blood and adipose tissue, in keeping with 
the anti- and pro-apoptotic roles of DHEAS and BCL2L11 (45,46), respectively. Taken 
together, these observations suggest that though independent variants may underlie the 
DHEAS and hormone-related cancer susceptibility signals at 2q13, the effects of both may 
be regulated through BCL2L11. While we were unable to highlight a particular target gene 
at the 11q12 three-cancer risk locus, the index variant and many linked SNPs lie in INCENP 
(Supplementary Fig. S1B) and the locus also includes MTA2 (467 kb from the index 
variant), another member of the NuRD complex (38). INCENP codes for the inner 
centromere protein, a non-enzymatic subunit of the chromosomal passenger complex (CPC; 
ref. (47)), that serves as the scaffold for CPC assembly (48). The CPC is a master regulator 
of mitosis and the inner centromere protein is essential for the activation and cellular 
localization of the enzymatic subunit of the CPC, Aurora B kinase (49), which is a much-
studied target with roles in multiple cancers (50). We have previously identified association 
between other correlated variants in INCENP and breast cancer susceptibility in a candidate 
gene study of CPC components though these associations did not reach genome-wide 
significance (51), further underscoring the utility of combining data across cancers to pick 
up far more robust signals.
Quantitative trait locus analysis identified a highly significant and directionally consistent 
cross-tissue association with L3MBTL3 expression for the 6q23 breast and prostate cancer 
index SNP. L3MBTL3 is a member of the malignant brain tumor (MBT) family of 
chromatin-modifying transcriptional repressors with histone code reading functions (52). 
Similarly, the eQTL data strongly suggested that RCCD1 was a shared cancer susceptibility 
gene at the 15q26 breast and ovarian cancer risk locus. It is worth noting that the index 
variant at this locus, rs8037137, is correlated with rs2290203 (r2 = 0.6, D′ = 1 in 1000 
Genomes European populations), which is a genome-wide significant index SNP for breast 
cancer predisposition in East Asians (Prs2290203 = 1.8 × 10−6 in our breast-ovarian meta-
analysis with same direction of effect as the East Asian breast cancer-specific signal; ref. 
(53)). SNPs in this region have not previously been associated with breast cancer risk in 
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Europeans or with ovarian cancer risk in any population. EQTL analysis in the East Asian 
study also identified the poorly characterized RCCD1 as the likely target gene of the locus. 
A combination of enhancer and eQTL mapping implicated NSUN4 as a potential breast and 
prostate cancer risk gene at 1p34. NSUN4 encodes a methyltransferase with an important 
role in mitochondrial ribosome production (54). The index variant (rs200182588) at the 
9q31 breast and ovarian cancer susceptibility locus lies in the 5′-untranslated region of 
SMC2 and binds several transcription factors in diverse tissue types including c-Myc in 
MCF7 cells (Supplementary Table S8). The structural maintenance of chromosomes 
protein-2 encoded by SMC2 is a core component of the condensin complex that is 
responsible for close packaging of chromatin before cell division (55). Moreover, SMC2 is a 
direct transcriptional target of oncogenic WNT signaling and N-Myc (56,57), and is 
emerging as a critical player in the DNA damage response (58). The index risk SNP at one 
of the seven new cross-cancer susceptibility loci discussed here was a genotyped SNP while 
at four other loci we were able to identify a genotyped SNP in the same region that was also 
genome-wide significant at P < 10−8. For the two remaining loci (9q31 and 11q12), the 
index SNPs were imputed SNPs (imputation accuracy > 0.8) and should be followed-up with 
confirmatory genotyping in additional samples.
Pathway analysis indicated significant involvement of induction of apoptosis through DR3 
and DR4/5 death receptor (DR) signaling in mediating global susceptibility to these three 
hormone-related cancers (35). In particular, our analysis revealed that 1 Mb windows around 
two SNPs on chromosomes 3 and 8 associated just short of genome-wide significance in the 
three-cancer meta-analysis (Prs3819772 = 7.6 × 10−8 and Prs10113131 = 9.5 × 10−7; 
Supplementary Table S9), harbored TNFSF10 that codes for the TNF-related apoptosis-
inducing ligand (TRAIL) and TNFRSF10A and TNFRSF10B that encode the two receptors 
of TRAIL, DR4 and DR5, respectively. DR5 expression in prostate cancer cells is androgen 
dependent and elevated levels of androgens have been shown to inhibit TRAIL-induced 
apoptosis in LNCaP (59). Likewise, most breast and ovarian cancer cell lines are resistant to 
TRAIL-induced apoptosis (60,61), likely due to estrogenic regulation of death receptor 
signals (62), endocytosis of cell surface DR4 and DR5 in breast cancer (63), and aberrant 
cleavage of the caspases in ovarian cancer (61). Given that recombinant TRAIL and its 
receptor agonist antibodies are already under development (64,65), the possible contribution 
of this druggable pathway to the risk of multiple hormone-related cancers might offer new 
avenues for early-stage cancer therapy.
In conclusion, we have demonstrated that pleiotropy or association of the same variant with 
multiple phenotypes, a genetic phenomenon recognized as early as Mendel’s classic 1866 
paper (66), can be tapped to combine genome-wide association data across cancer types and 
uncover several risk loci that are shared by – and represent novel findings for – breast, 
ovarian, and prostate cancer. Our preliminary in silico characterization of the new loci also 
suggests that the integration of orthogonal resources such as eQTL and enhancer annotations 
from different cell types enabled by cross-cancer site strategies may refine the post-GWAS 
identification of putative functional target genes at cancer risk loci (67). Finally, the 
increased power of pleiotropy-informed locus discovery, fine mapping, pathway analysis, 
and polygenic risk prediction over conventional single-cancer approaches has the potential 
to offer fresh insights into the common biology that may underpin susceptibility to these 
Kar et al. Page 10
Cancer Discov. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
three hormone-related cancers, with implications for cross-cancer genetic screening (68). 
This work thus illustrates the need for even larger pan-cancer genome-wide association 
meta-analyses that include data from a broad range of cancer types including the other 
hormone-related cancers.
Methods
Breast, Ovarian and Prostate Cancer Data Sets
The data sets contained SNP-level summary statistics from association analyses for cancer 
risk from a published meta-analysis of genome-wide association study (GWAS) discovery, 
replication, and custom genotyping case-control studies for each cancer. The relevant local 
institutional review board approved each of these studies, informed consent was obtained 
from participants, and the studies were conducted in accordance with the Declaration of 
Helsinki. Details of the study participants, genotyping, quality control, imputation, 
association analysis and meta-analysis for each data set have been previously described (7–
9). All analyses in the current study were restricted to data from individuals of European 
ancestry. Genotypes in each data set had been imputed into the March 2012 release of the 
1000 Genomes Project European ancestry reference panel (version 3 of the Phase 1 
integrated variant set release; ref. (69)). We only considered results for variants imputed with 
imputation accuracy, r2 > 0.3. Imputation accuracy estimates were calculated in samples 
from the Collaborative Oncological Gene-Environment Study (COGS; ref. (70)) since they 
comprised the largest subset of each data set. In addition to summary statistics for 
association with susceptibility to overall breast cancer, all invasive epithelial ovarian cancer, 
and overall prostate cancer, we also used summary results for association with estrogen 
receptor-negative breast cancer and serous epithelial ovarian cancer risks.
Compilation of the list of published breast, ovarian, and prostate cancer index SNPs is 
described under Supplementary Methods.
Meta-analysis
Estimated magnitudes of association (beta coefficients) and standard errors for variants from 
each data set were combined assuming fixed effects using inverse-variance weighted meta-
analysis implemented in METAL (71). Heterogeneity in the per-allele odds ratio between 
cancers was assessed using P-values from Cochran’s Q-statistic also calculated by METAL. 
All linkage disequilibrium (LD) calculations (r2 and D′) presented were performed using the 
LDlink suite and data from the 1000 Genomes Project European ancestry populations 
(69,72).
Alleles with Opposite Effects and Contribution of Each Data Set to Association Signals
To identify alleles that confer risk of one cancer but are protective for another cancer in each 
two-cancer meta-analysis, we reversed the signs on the beta coefficients in one of the two 
data sets and repeated the corresponding meta-analysis as done previously by Zhernakova et 
al. (ref. (22)). To identify alleles sharing associations with breast, ovarian, and prostate 
cancer risk where the direction of allelic effect on any one of these cancers was opposite to 
that observed for the other two, we used the two-sided subset search function in the 
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association analysis based on subsets (ASSET) R package (version 1.0.0) (20). Specifically, 
we used the h.traits function with arguments set as follows: side=2, meth.pval=c(“DLM”), 
and search=2. This function in ASSET searches for such alleles for subsets of data sets (in 
this case representing phenotypes or cancers) and calculates fixed-effects meta-analysis-style 
test statistics separately for each subset (that is, for two cancers in one direction and the third 
cancer in the opposite direction). The two test statistics are then combined using a Chi-
squared statistic and corrected for the multiple subset searches conducted. We also used the 
model-selection function in ASSET to identify the subset of data sets or cancer types in each 
meta-analysis that contributed to the overall association signal at the newly identified index 
variants.
Overlapping Controls Between the Breast and Ovarian Cancer Studies
An overlap of 8,548 controls existed between the breast and ovarian cancer data sets. To 
account for correlation between the data sets due to overlapping controls, we applied a 
general statistical decoupling framework that involves adjusting the standard errors of each 
variant from the dependent data sets using a correlation matrix generated from the sample 
overlap counts (21). The data sets can then be analyzed as independent data sets. The 
correlation matrix itself was calculated as previously described (73). Correlations between 
the overall breast and all invasive epithelial ovarian cancer data sets and between the ER-
negative breast and serous ovarian cancer data sets were found to be ~8% and ~4%, 
respectively. We applied the decoupling framework using exact counts for samples 
contributing to the association at the index variant in each new region identified at P < 10−8 
in any meta-analysis involving both the breast and ovarian cancer studies and repeated the 
corresponding meta-analysis using METAL to confirm the signal for the variant after 
adjustment of standard errors.
Expression QTL Analyses
Expression QTL analysis results for each index variant at the seven loci listed in Table 2 and 
all genes within 1 Mb of it were looked up using the Genotype-Tissue Expression (GTEx) 
project Portal in normal breast (n = 183), ovarian (n = 85), and prostate (n = 87) tissue 
samples (23). To improve the power to detect significant eQTLs, at the cost of losing tissue-
specificity, we also performed the same searches (where data availability permitted) in the 
blood eQTL browser that is based on eQTL analysis in peripheral blood samples from 5,311 
individuals (24).
Enhancer-Gene Interactions
Maps of enhancer regions with predicted target genes were obtained from Hnisz et al. (26), 
Corradin et al. (28), and He et al (27). Enhancers active in the breast cell types HMEC 
(normal), MCF-7 (cancer), and HCC1954 (cancer), normal ovarian cell types from UCSD, 
and the prostate cancer cell line LNCaP (as relevant to each locus) were intersected with all 
variants with P < 10−8 in the seven regions listed in Table 2 using Galaxy. ENCODE 
Chromatin Interaction Analysis by Paired-End Tag sequencing (ChIA-PET) data from 
MCF-7 cells (mediated by RNA polymerase 2 and ERα) were downloaded using the UCSC 
Table browser (30). Galaxy was used to identify the ChIA-PET interactions between an 
implicated breast cell enhancer (containing a strongly associated variant) and a predicted 
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gene promoter (defined as regions 3 kb upstream and 1 kb downstream of the transcription 
start site).
Functional Annotation
We annotated all variants with P < 10−8 at the seven loci listed in Table 2 using the 
HaploReg v3 pipeline (31). Variants were annotated with (a) their location within a gene or 
distance from the nearest gene, (b) their functional consequence as per dbSNP if they were 
intragenic (intronic; located in the 3′- or 5′-untranslated region; exonic: synonymous or 
nonsynonymous), (c) GERP and SiPhy conservation scores (74,75), (d) effect on regulatory 
(transcription factor binding) motifs calculated using position weight matrices obtained from 
TRANSFAC (76), JASPAR (77), and other sources(78), and (e) transcription factor binding 
data from ENCODE (78). We also annotated these SNPs based on whether they were 
located in long non-coding RNAs and microRNAs or microRNA seed regions and target 
sites (32,33). Regional association plots that integrated 1000 Genomes LD data with gene 
annotation tracks were generated using LocusZoom (79).
LD-based Pruning and Pathway Analysis
All (884) alleles demonstrating the same direction of effect across cancers without 
significant heterogeneity in the per-allele odds ratio (Phet > 0.05) and with association P-
values < 10−5 in the meta-analysis of the three cancers were subjected to LD-based 
‘pruning’ (80). Starting with the most significantly associated variant, all variants within 1 
Mb of it with correlation, r2 > 0.1 (calculated using 1000 Genomes Project European 
population genotype data) were removed. This was followed by a second round of LD-
pruning with the same r2 threshold but for a distance of 10 Mb to remove variants in long-
range LD. This yielded 69 independent variants. Assuming that a variant could potentially 
regulate any gene up to 1 Mb on either side of it (81), we generated 69 2-Mb-wide intervals 
such that each was centered on one variant. Merging overlapping intervals left 51 intervals.
The Interval Enrichment (INRICH; ref. (34)) tool was used to permute 5,000 sets of 
intervals with each set reasonably well-matched to the original set of 51 intervals in terms of 
interval size, number of genes and variants per interval, and variant positions (sampled based 
on hg19 gene and 1000 Genomes variant location data). The permuted sets were used to 
calculate an empirical P-value for enrichment of genes from a particular pathway among the 
observed intervals. A second permutation step (1,000 permutations) was applied to correct 
for multiple comparisons at the pathway level. All pathways containing between 20 and 200 
genes from four extensively-curated online pathway repositories: Biocarta, the Kyoto 
Encyclopedia of Genes and Genomes (KEGG), Reactome, and Gene Ontology were 
obtained from the Molecular Signatures Database (MSigDB v3.0; (82)). Four pathway 
databases were used because each has a distinct and largely complementary approach to 
capturing known biological pathways (83). However, considerable overlap was present in 
gene content of the common pathways across databases and therefore we applied INRICH 
separately to pathways from each database. The different types of biological interactions 
shown in Supplementary Figure 3 between BCL2L11 and the genes in the Biocarta 
induction of apoptosis through DR3 and DR4/5 Death Receptors pathway were identified 
using the GeneMania server (84).
Kar et al. Page 13
Cancer Discov. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
We demonstrate that combining large-scale genome-wide association meta-analysis 
findings across cancer types can identify completely new risk loci in common to breast, 
ovarian, and prostate cancer. We show that the identification of such cross-cancer risk 
loci has the potential to shed new light on the shared biology underlying these hormone-
related cancers.
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Figure 1. 
Manhattan plot of results from the combined breast, ovarian, and prostate cancer meta-
analysis. The black and gray dots represent the 2,231 variants nominally associated (P < 
0.05) with every cancer type individually that had the same direction of effect across all 
three cancers. The red line corresponds to a threshold of P = 10−8. Eighteen independent loci 
were identified at this threshold. The green dots highlight index SNPs at 11 loci out of these 
18 where model selection using ASSET confirmed contribution from all three cancer types 
to the association signal and that remained at P < 10−8 after adjusting for the controls shared 
between the breast and ovarian cancer studies. Gene names identify the three loci out of the 
11 that were > 1 Mb away from previously identified index SNPs for any of the three 
cancers.
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Figure 2. 
Forest plots of odds ratio estimates for the new cross-cancer index SNPs (> 1 Mb from 
known index SNPs) for susceptibility to (A) breast, ovarian, and prostate cancer and (B) 
breast and ovarian cancer, and breast and prostate cancer. Error bars indicate 95% 
confidence intervals and het_P is the P-value calculated from Cochran’s Q-test for 
heterogeneity.
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Figure 3. 
Regional association plot of results from the three-cancer meta-analysis for the 
rs1469713/19p13 breast, ovarian, and prostate cancer susceptibility locus. The black dots 
represent all variants nominally associated (P < 0.05) with every cancer type individually 
that had the same direction of effect across all three cancers. The purple dashed line 
corresponds to a threshold of P = 10−8. Tracks immediately below the regional association 
plot show the locations of enhancers in breast (pink), ovarian (green), and prostate (blue) 
cell types. Interactions derived from ChIA-PET experiments, which have only been assayed 
in breast cells, are labeled as experimental interactions. Where the same gene is predicted to 
be a target of enhancers that intersect with the same P < 10−8 SNP in all three cell types (or 
two for the 2q13 region), it is shown in red. All other genes in the region are in gray. The 
corresponding P < 10−8 SNP locations are marked by grey vertical stripes. The lower tracks 
show arcs between enhancers and target genes for both computationally predicted and 
experimentally derived interactions. Arc colors reflect the cell type in which the enhancer-
promoter pair was identified.
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Figure 4. 
Regional association plot of results from the three-cancer meta-analysis for the 
rs17041869/2q13 breast, ovarian, and prostate cancer susceptibility locus. The black dots 
represent all variants nominally associated (P < 0.05) with every cancer type individually 
that had the same direction of effect across all three cancers. The purple dashed line 
corresponds to a threshold of P = 10−8. Tracks immediately below the regional association 
plot show the locations of enhancers in breast (pink), ovarian (green), and prostate (blue) 
cell types. Interactions derived from ChIA-PET experiments, which have only been assayed 
in breast cells, are labeled as experimental interactions. Where the same gene is predicted to 
be a target of enhancers that intersect with the same P < 10−8 SNP in all three cell types (or 
two for the 2q13 region), it is shown in red. All other genes in the region are in gray. The 
corresponding P < 10−8 SNP locations are marked by grey vertical stripes. The lower tracks 
show arcs between enhancers and target genes for both computationally predicted and 
experimentally derived interactions. Arc colors reflect the cell type in which the enhancer-
promoter pair was identified.
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